{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:44:47Z","timestamp":1772826287201,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Immediate postoperative anticoagulation regimens in patients with mechanical prosthetic valves undergoing non-cardiac surgery are clear only for unfractionated heparin (UH), whereas the few low-molecular-weight heparin (LMWH) trials available to date concern the use of Enoxaparin in general\/orthopedic surgery. We performed a single-center real-world data study comparing the efficacy and safety of LMWH\u2014Enoxaparin (E)\u2014 and UH during the perioperative period in non-cardiac surgical procedures in patients with mechanical prosthetic valve replacement in the mitral, aortic, or tricuspid positions. Materials and Methods: We enrolled 380 patients, who received E or UH together with oral anticoagulation with antivitamin K (acenocoumarol) until they achieved an optimal International Normalized Ratio (INR). Objective assessment of E efficacy included the following: normal value for all the parameters of ultrasound prosthetic functioning, no early thrombosis of the prosthesis, and rapid achievement of target INR with a decreased period of subcutaneous anticoagulation. Subjective assessment included the following: clinical improvement with decreased immobilization and in-hospital stay, fewer gluteal ulcerations, and fewer postoperative depression and anxiety episodes. Results: Comparing with UH, anticoagulation with E was more effective (p &lt; 0.0001 and p = 0.02). The probability of death was smaller in the E group compared with the UH group. No major hemorrhagic event was reported. Mild bleeding episodes and thrombocytopenia were more common in the UH group. Patient\u2019s compliance and quality of life were better with E due to shortened hospitalization, decreased need for testing of coagulation (every 6 h for UH), better dosing (SC every 12 h for E versus continuous infusion for UH), shortened immobilization during the immediate postoperative period with subsequent improvement in the psychological status, as well as due to lack of significant side effects. Conclusions: Taking into consideration the improved efficiency and safety, as well as all the supplementary advantages, such as no need for anticoagulation monitoring, the ease of administration, and reduced duration of hospitalization, E should be seen as an attractive alternative for anticoagulation which deserves further investigation.<\/jats:p>","DOI":"10.3390\/medicina58081119","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T23:28:41Z","timestamp":1660865321000},"page":"1119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-5002","authenticated-orcid":false,"given":"Luminita","family":"Iliuta","sequence":"first","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Cardioclass Clinic for Cardiovascular Disease, 031125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5590-7879","authenticated-orcid":false,"given":"Andreea","family":"Andronesi","sequence":"additional","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Camburu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-9792","authenticated-orcid":false,"given":"Marius","family":"Rac-Albu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Cardioclass Clinic for Cardiovascular Disease, 031125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2015.08.002","article-title":"Bridging Anticoagulation: Primum Non Nocere","volume":"66","author":"Rechenmacher","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"Andersson","year":"2012","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/HCO.0000000000000259","article-title":"Anticoagulation for prosthetic heart valves: Unresolved questions requiring answers","volume":"31","author":"Yanagawa","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_7","first-page":"833","article-title":"Low Molecular Weight Heparin versus Unfractionated heparin for The Perioperative Anticoagulant Therapy in Patients Undergoing Mechanical Prosthetic Valve Replacement","volume":"27","author":"Iliuta","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2141.2003.04196.x","article-title":"Low-molecular-weight heparins: Are they all the same?","volume":"121","author":"White","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijsu.2018.04.059","article-title":"Low molecular weight heparin for the prevention of deep venous thrombosis after total knee arthroplasty: A systematic review and meta-analysis","volume":"54","author":"Xia","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/CIRCULATIONAHA.105.575571","article-title":"Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement","volume":"113","author":"Meurin","year":"2006","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.athoracsur.2013.09.040","article-title":"Exclusive low-molecular-weight heparin as bridging anticoagulant after mechanical valve replacement","volume":"97","author":"Kindo","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_14","first-page":"CD001100","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","volume":"8","author":"Erkens","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9149(99)00341-0","article-title":"Use of enoxaparine for the chronically anticoagulated patient before and after procedures","volume":"84","author":"Spandorfer","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2710.2008.00959.x","article-title":"Managing oral anticoagulation therapy: Improving clinical outcomes. A review","volume":"33","author":"Ryan","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin. Kidney J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:53Z","timestamp":1760141513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["medicina58081119"],"URL":"https:\/\/doi.org\/10.3390\/medicina58081119","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}